Market revenue in 2023 | USD 88.8 million |
Market revenue in 2030 | USD 139.8 million |
Growth rate | 6.7% (CAGR from 2023 to 2030) |
Largest segment | Factor i |
Fastest growing segment | Factor I |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Factor I |
Key market players worldwide | Novo Nordisk A/S ADR, Biogen Inc, Bayer AG, Pfizer Inc, Takeda Pharmaceutical Co Ltd, Baxalta, CSL Ltd, Bio Products Laboratory |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare hemophilia factors market will help companies and investors design strategic landscapes.
Factor i was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Europe rare hemophilia factors market based on factor i covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe rare hemophilia factors market , including forecasts for subscribers. This continent databook contains high-level insights into Europe rare hemophilia factors market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account